Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: A gynecologic oncology group study☆,☆☆
References (6)
- Benjamin, R., Keating, M., Valdivieso, M., et al. Phase I–II study of piperazinedione in adults with solid tumors and...
- et al.
Platinum compounds: A new class of potent antitumor agents
Nature (London)
(1969) - et al.
Phase II studies in advanced, recurrent pelvic malignancies conducted by the Gynecologic Oncology Group (GOG): Experimental design and experience
Amer. J. Clin. Oncol.
(1982)
Cited by (31)
Vulvar cancer management and wrangling recurrent disease: A report from the society of gynecologic oncology journal club
2023, Gynecologic Oncology ReportsEfficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study
2022, Gynecologic OncologyCitation Excerpt :Treatment options for recurrent or metastatic vulvar cancer are limited, and no clear standard-of-care treatment exists [6]. Despite resistance to chemotherapy [7–11], advanced recurrent or metastatic vulvar cancer has generally been treated with chemotherapy or chemoradiation [6]. Recent studies have evaluated additional treatment options, including immunotherapy, in patients with vulvar cancer.
Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
2020, Gynecologic Oncology ReportsCitation Excerpt :Many systemic therapies have been studied with limited success in improving overall survival in advanced vulvar carcinoma in recent decades (Ramanah et al., 2012). Prior studies have historically revealed a relatively poor response to chemotherapy alone suggesting an element of chemoresistance in vulvar carcinoma (Reade et al., 2014; Thigpen et al., 1986). One prior phase II study examined the efficacy of cisplatin in the treatment of vulvar carcinoma, which revealed a 0% response rate (Thigpen et al., 1986).
Identification of molecular targets in vulvar cancers
2017, Gynecologic OncologyCitation Excerpt :The NCCN guidelines incorporate chemotherapies used for other HPV-induced cancers, including cisplatin, mitomycin-C, 5-fluorouracil, vinorelbine, and paclitaxel; however, given the paucity of data due to the rarity of this disease, targeted therapies are lacking from these recommendations. Chemotherapeutic agents that are active in other squamous cell cancers have proven to be less effective in vulvar carcinoma [11–13]. Some targeted therapies have been approved for other HPV-related SCC, including bevacizumab for advanced or recurrent cervical cancer and cetuximab for head and neck cancer.
Cancers of the Vulva and Vagina
2015, Clinical Radiation Oncology
- ☆
Address for reprint requests: GOG Headquarters, Suite 1945, 1234 Market Street, Philadelphia, Pa. 19107.
- ☆☆
The following are participating institutions and their National Cancer Institute grants supporting this study. Duke University Medical Center (CA 12534), George Washington University Medical Center (CA 16938), Hahnemann Medical College/Jefferson Medical College (CA 12478), New York Medical College (CA 12483), University of Rochester Medical Center (CA 12482), University of Mississippi Medical Center (CA 13633), Colorado Foundation for Medical Care (CA 15975), University of California Medical Center at Los Angeles (CA 13630), The Milton S. Hershey School of Medicine of Pennsylvania State University (CA 16386), Georgetown University Hospital (CA 16938), University of North Carolina School of Medicine (CA 23073), Bowman Gray School of Medicine of Wake Forest University (CA 21946), The Albany Medical College of Union University (unfunded), University of California Medical Center at Irvine (CA 23765), Tufts New England Medical Center (CA 37569), Illinois Cancer Council (CA 27806), and St. Louis University Medical Center (CA 35571).